+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis

  • ID: 4655559
  • Report
  • February 2018
  • Region: Global
  • 29 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Genentech
  • GSK
  • Roche
  • Sanofi
  • UCB
  • MORE
KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis

Summary

This KOL Insight briefing focuses on perceptions of IL-6 inhibitors in rheumatoid arthritis (RA).

The briefing includes analysis of KOL opinion on the following topic areas:
  • Current or anticipated future use of sarilumab in RA
  • Current use of tocilizumab in RA
  • Expected future change to sarilumab & tocilizumab use
  • Comparison of sarilumab & tocilizumab clinical profile in RA
  • Non-clinical differentiating factors between sarilumab & tocilizumab
  • Impact of and factors contributing to sirukumab discontinuation in RA
  • IL-6 inhibitors vs. JAK inhibitors in RA
  • KOL awareness of olokizumab currently in development for RA
Key Highlights:
  • Majority of US but not EU patients have access to sarilumab, with KOLs primarily positioning sarilumab in MTX-IR patients or after anti-TNFs
  • Most KOLs position tocilizumab after anti-TNFs, partly due to payer pressure, with first-line use possible in MTX-IR or ineligible patients
  • In the next 12 months, most KOLs expect an increase in use of sarilumab, and a reduction in use of tocilizumab.
Scope
  • The briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs)
  • In total, we conducted interviews with 10 KOLs: Five Europe-based & five US-based
  • Interviews performed in December 2017
  • KOL data is analyzed to produce: Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts.
Reasons to buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on "IL-6 inhibitors in Rheumatoid Arthritis"
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of rheumatoid arthritis
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Genentech
  • GSK
  • Roche
  • Sanofi
  • UCB
  • MORE
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Sanofi
  • Roche
  • Genentech
  • UCB
  • GSK
Note: Product cover images may vary from those shown
Adroll
adroll